The effect of HCJ0152, a STAT3 inhibitor on Chronic Myelogenous Leukemia cell line-K562

Abstract

Overexpression of signal transducer and activator of transcription 3 (STAT3) has been found in cancer patients, particularly in CML, and because HJCO0152 is a signaling pathway inhibitor, it may have anti-cancer benefits in this condition and play a function as a signaling pathway inhibitor. The impact of HJC0152 on the K562 cancer cell line was studied in this study. Materials and methods In this research, MTT was used to assess cell proliferation, Western blotting was used to assess protein levels, flow cytometry was used to evaluate apoptosis, and the expression of the Bcl-2, Bax, Caspase3, and Caspase9 genes, and the STAT3 gene. Results HJC0152 may drastically reduce K562 cell growth and cause apoptosis, as well as diminish STAT3 expression and prevent its phosphorylation and therefore activation, according to the findings of this study. Genes that are found downstream of the signaling pathway are being studied and also have a beneficial effect on apoptosis-related genes in CML.